Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: Fibrogenesis-driven tumor progression in clear cell renal cell carcinoma: prognostic, therapeutic implications and the dual role of neuropilin-1

Fig. 6

TME, immunotherapy and drug sensitivity analysis between high- and low- risk groups. A Immune landscape obtained by various algorithms with clinical features. B Comparison of the distribution of stroma, immune, ESTIMATE score and tumor purity. C Higher abundance of fibroblasts in high-risk group. D TIDE, Dysfintion, Exclusion and MDSC scoring by TIDE algorithm. E Differences in immune subtype between risk groups. F Immunophenoscore (IPS) comparison between different risk groups. G Classical immune checkpoint genes expression level. H Mutation landscapes. I Potential drug screening for different risk groups and correlation between IC50 and risk scores

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us